News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Athenex Announces Recent Product Launches In Commercial Business



8/1/2017 1:47:35 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Highlight Athenex Pharmaceutical Division’s Growing Portfolio

BUFFALO, N.Y., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced recent product launches from Athenex Pharmaceutical Division (‘APD”). These launches highlight Athenex’s growing commercial portfolio and strong relationships with FDA approved partners worldwide.

Athenex has brought the following products to market in its Specialty (finished-dose specialty injectable products) and 503B (outsourced sterile preparations) businesses:

Specialty Products

  • Oxaliplatin 5mg/mL, 10 mL; 5 mg/mL, 20 mL; (2 SKUs; vials)
  • Vancomycin 500 mg; 1 g; (2 SKUs; vials)
  • Polymyxin B 500,000 units; (1 SKU; vial)
  • Ketorolac 15 mg/mL 1 mL; 30 mg/mL 1 mL; 30 mg/mL 2 mL (3 SKUs; vials)
  • Midazolam 2mg/2 mL; 25 mg/5 mL; 50 mg/10 mL; (3 SKUs; vials)
  • Terbutaline Sulfate Injection 1mg/1 mL; (1 SKU; vial)
  • Tranexamic Acid 100 mg/ml 10 mL (1 SKU; vial)

503B Products

  • Epinephrine in 250 mL Dextrose bags (2 SKUs)
  • Norepinephrine in 250 mL Dextrose bags (3 SKUs)
  • Phenylephrine in 250 mL Saline bags (5 SKUs)

Jeffrey Yordon, Athenex’s Chief Operating Officer and President of APD, stated, “We are proud to bring so many products to the U.S. market in our first year as a commercial entity. These launches underscore the capabilities of our Commercial business, as well as the strength of our partner relationships. We remain focused on expanding our pharmaceuticals business and expect to see additional product launches from our commercial business by year-end. The infrastructure and capabilities we are building through our specialty pharmaceutical business not only allow Athenex to rapidly expand our product portfolio, but also provide us with a strong commercial platform and broad-ranging expertise to leverage across our proprietary platform.”

Athenex’s products emphasize quality and enhance patient safety. cGMP processes are followed for each of Athenex’s products, and a Certificate of Analysis is provided for each batch of 503B products so customers are able to see measurable results from repeatable tests. Additionally, Athenex’s AccuraSEE, a proprietary and highly differentiated approach to package and labeling, has a unique design to give caregivers accurate information and reduce the risk of medication errors.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites, human absorption biology and through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York, Cranford, New Jersey, Houston, Texas, Chicago, Illinois, Hong Kong, Taipei Taiwan, and multiple locations in Chongqing, China.

CONTACT: Nick Riehle Tel: +1-716-427-2952 Athenex, Inc.

Read at BioSpace.com


comments powered by Disqus
Athenex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES